FDA Approves LECANEMAB AUTOINJECTOR — Eisai Inc.

Eisai Inc. announced Friday the FDA approval of the subcutaneous lecanemab (Leqembi) formulation, expanding the treatment accessibility for early Alzheimer’s disease just a week after the intravenous version was approved. This strategic expansion is expected to significantly broaden the drug's addressable patient pool by eliminating the need for infusion centers, thereby potentially driving substantial market share gains amidst growing competition in the Alzheimer's landscape.